

MicroRNA-32 Upregulation by 1,25-Dihydroxyvitamin D₃ in Human Myeloid Leukemia Cells Leads to Bim Targeting and Inhibition of AraC-Induced Apoptosis

Elzbieta Gocek^{1,2}, Xuening Wang¹, Xiuping Liu³, Chang-Gong Liu³, and George P. Studzinski¹

Abstract

1,25-Dihydroxyvitamin D₃ (1,25D) used to treat human acute myeloid leukemia (AML) cells induces features of normal monocytes, but the mechanisms underlying this response are not fully understood. We hypothesized that one or more microRNAs (miRNA) known to control mouse hematopoiesis and lineage commitment might contribute to the ability of 1,25D to control the malignant phenotype. Here we report that 1,25D markedly induces expression of miR-32 in human myeloid leukemia cells, in which it targets the 3'-untranslated region of the mRNA encoding the proapoptotic factor Bim to reduce its expression. RNAi-mediated suppression of the miRNA-processing enzymes Drosha and Dicer increased Bim levels, in support of the concept that Bim is under miRNA control in AML cells. Antisense-mediated suppression of miR-32 was sufficient to upregulate Bim expression in AML cells. Conversely, ectopic expression of miR-32 downregulated Bim expression and increased the differentiation response to 1,25D treatment in a manner that was associated with increased cell survival. The positive effects of miR-32 on cell survival were confirmed by evidence of increased cell death in AML cells preexposed to antisense miR-32 before treatment with arabinocytosine, a chemotherapeutic drug used to treat human AML. Together, our findings indicate that miR-32 blockade is sufficient to elevate Bim expression and sensitize AML cells to chemotherapy-induced apoptosis. Thus, agents which can inhibit miR-32 expression may offer clinical utility by enhancing therapeutic efficacy in human AML. *Cancer Res*; 71(19); 6230–9. ©2011 AACR.

Introduction

Acute myeloid leukemia (AML) is a hematologic disease characterized by blocks at various stages of hematopoietic differentiation, which lead to uncontrolled cell proliferation and accumulation of immature myeloid cells in bone marrow and the peripheral blood. The disease has extremely poor prognosis, even with the available treatment regimens, which currently are based on the eradication of the malignant stem and myeloid precursor cells (blasts) by cytotoxic agents such as arabinocytosine (AraC). Unfortunately, toxicity of these drugs to the patients limits their dosage, and recurrences of the disease are frequent (1). Thus, effective other treatment modalities are urgently needed.

The differentiation blocks responsible for the disease can be overcome in cultured AML cells by supraphysiologic concentrations of the active form of vitamin D, 1,25-dihydroxyvitamin

D₃ (1,25D; refs. 2–4). The rationale for the ability of 1,25D to achieve this effect has been presented as due to an elevation of the levels of transcription factors (TF), for example, jun/AP1 and C/EBP beta, which permit the blasts to bypass the barrier presented by the leukemia-causing mutations, frequently by a switch from myeloid to monocytic differentiation lineage induced by these TFs (5–9). However, although all-trans retinoic acid (ATRA) has been successfully used in the clinic, induction of differentiation of AML blasts by 1,25D has so far not resulted in notable clinical success. The reasons for this may include the fact that in addition to prodifferentiation activity, ATRA also promotes cell death and is particularly effective when combined with arsenic trioxide, a toxic agent (10, 11). Similarly, increased cytotoxicity is seen when, following AraC exposure, 1,25D is added to cultured AML cells (12, 13). It seems reasonable, therefore, to explore whether changes in cell survival mechanisms that accompany 1,25D-induced differentiation can be modified to increase the therapeutic potential of 1,25D.

Using a miRNA microarray platform, we observed that miR-32 was the most highly elevated miRNA in human leukemia 60 (HL60) cells treated with 1,25D. One of the predicted targets of miR-32 lies in the 3'-untranslated region (UTR) of *BCL2L1* gene, which encodes the proapoptotic protein Bim (14, 15). Therefore, we investigated whether the increased levels of miR-32 in 1,25D-treated AML cells can be validated by quantitative real time PCR (qRT-PCR), and if so, whether miR-32 regulates the expression of Bim, and whether this is

Authors' Affiliations: ¹Department of Pathology and Laboratory Medicine, UMD–New Jersey Medical School, Newark, New Jersey; ²Faculty of Biotechnology, University of Wrocław, Wrocław, Poland; and ³Department of Experimental Therapeutics–Unit 36, Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas

Corresponding Author: George P. Studzinski, Department of Pathology and Laboratory Medicine, UMD–New Jersey Medical School, 185 South Orange Ave., Newark, NJ 07101. Phone: 973-972-5869; Fax: 973-972-7293; E-mail: studzins@umdnj.edu

doi: 10.1158/0008-5472.CAN-11-1717

©2011 American Association for Cancer Research.

associated with changes in the ability of cytotoxic agents, such as AraC, to induce the death of AML cells.

Materials and Methods

Cell culture

HL60-G cells, derived from a patient with promyeloblastic leukemia (16), and U937 cells, obtained from American Type Culture Collection were cultured in suspension in RPMI-1640 medium supplemented with 10% bovine calf serum (Hyclone) in a humidified atmosphere containing 5% CO₂ at 37°C. For U937 cells concentration of 1,25D routinely used was 10 nmol/L, as these cells are less sensitive to 1,25D than HL60 cells, which were treated with 1 nmol/L 1,25D. Cells were passaged 2 to 3 times a week and were used in the exponential growth phase. Cells were routinely tested for *Mycoplasma* by selective culture techniques. For all experiments the cells were resuspended in fresh medium, and each experiment was repeated at least 3 times.

Isolation of mononuclear cells from peripheral blood and selection of monocytes

Peripheral blood samples were obtained from 5 healthy volunteers according to Institutional Review Board protocol. Mononuclear cells were isolated by using Histopaque-1077 (Sigma-Aldrich), as previously described (17). Monocytes were positively selected with CD14 MicroBeads (Miltenyi Biotec Inc.) as directed by manufacturer's protocol. Homogeneity of CD14-positive cells was determined by using EPICS XL flow cytometer (Beckman Coulter).

Chemicals and antibodies

1,25D was a kind gift from Dr. Milan Uskokovic (Bioxell). Antisense oligonucleotides against Drosha (Cat#L-016996-00) and Dicer (Cat#L-003483-00) were obtained from Thermo Scientific, hsa-miR-32 anti-miR miRNA inhibitor (ID: AM12716) and hsa-miR-32 pre-miR miRNA precursor (ID: PM12716) were obtained from Applied Biosystems. Complete protease inhibitor cocktail was purchased from Hoffmann-La Roche. Antibodies were procured from Cell Signaling Technologies [Bim, Bax, secondary anti-rabbit, and anti-mouse linked to horseradish peroxidase (HRP)] and from Santa Cruz Biotechnology (Crk-L and Calregulin).

MicroRNA target predictions and pathway analysis

Public web-based prediction sites under miRbase were used to identify miRNA 32 target binding sites in the 3'-UTR of human gene transcripts (18). miRBase currently links miRNA-32 to targets predicted by microcosm Targets (19), microRNA.org (20), TargetScan (21), and Pictar-Vert (22), and aims to provide a more extensive target prediction aggregation service in the future. In addition, other target prediction online softwares (DIANA-microT, miRanda, and PITA) were used. Targets of miRNAs which were differentially and significantly (>1.5-fold change and $P < 0.05$) expressed by 1,25D were subjected to Ingenuity Pathway Analysis (IPA; Ingenuity Systems) done by uploading specific miRNA lists into miRNA array analysis program. The list of gene targets of miRNAs predicted by IPA was filtered to remove duplicates and genes

with no annotation in IPA listed apoptosis pathways, resulting in a list of network-eligible genes associated with the apoptosis signaling pathway.

Transfection of siRNA against Drosha and Dicer, of antisense oligonucleotides against miR-32, and of miR-32 precursor

This was carried out using Endo-Porter delivery reagent from Gene Tools Inc. Si-Drosha, si-Dicer (Thermo Scientific), anti-miR-32 inhibitor (a chemically modified, single-stranded nucleic acid designed to specifically bind to and inhibit endogenous miRNA molecules), pre-miR-32 (Ambion) and appropriate nontargeting control oligonucleotides were transfected at a final concentration of 20 nmol/L for 48 hours before exposure to other compounds.

RNA isolation and qRT-PCR

Total RNA was extracted by using Trizol (Invitrogen) according to manufacturer's protocol and reverse transcribed for quantification by TaqMan microRNA Reverse Transcription Kit (Applied Biosystems) as previously described (23). Mature miRNAs were quantitated using 2-step TaqMan RT-PCR with TaqMan microRNA kit. MiR-32 expression level was normalized using U6 rRNA as an internal control (Applied Biosystems).

qRT-PCR for Bim was carried out using a FastStart DNA SYBR Green PCR kit (Roche Diagnostics) as described before (23). Fold changes of mRNA levels in target gene relative to the RNA polymerase II (RPII) control were calculated by relative quantification analysis. Primers used for Bim were as follows: upstream 5'-AGTTCTGAGTGTGACCGAGAAGGT-3', downstream 5'-TCCTGTCTTGTGGCTCTGTCTGT A-3'; for RP II, upstream 5'-GCACCACGTCCAATGACAT-3', downstream 5'-GTGCGG CTGCTTCCATAA-3'. The quality of PCR products were monitored using post-PCR melting curve analysis.

Markers of monocytic differentiation

Aliquots of 1×10^5 cells were harvested, washed twice with PBS and incubated for 45 minutes at room temperature with 0.5 μ L MY4-RD-1 and 0.5 μ L MO1-FITC (fluorescein isothiocyanate) antibodies (Beckman Coulter Inc.) to analyze the expression of monocytic differentiation surface markers CD14 and CD11b, respectively. The cells were then washed 3 times with ice-cold PBS, resuspended in 1 mL PBS, and analyzed using EPICS XL flow cytometer (Beckman Coulter). Isotypic mouse IgG1 was used to set threshold parameters.

Cell-cycle distribution

The DNA content of the cells was determined as follows: 1×10^6 cells were harvested and washed twice with PBS, then fixed with 75% ethanol at -20°C for 24 hours. Cells were then collected and resuspended in 1 mL of PBS with 10 μ g/mL RNase (Sigma) and 10 μ g/mL propidium iodide (PI; Sigma) for 30 minutes at 37°C. PI-stained cells were analyzed using EPICS XL flow cytometer. The resultant distribution of DNA content was gated and analyzed using the multicycle program to determine the proportion of cells in the sub-G₁/G₀ fraction, which represents the nonviable cells.




Figure 1. Expression levels of miR-32 are upregulated by 1,25D in HL60 and U937 cells. HL60 cells were exposed to 1 nmol/L 1,25D for 48 hours, and the less sensitive U937 cells to 10 nmol/L 1,25D for 72 hours, whereas normal monocytes to 100 nmol/L 1,25D for 96 hours. The miR-32 expression level was estimated using (A) miRNA microarray platform (24) and (B) TaqMan qRT-PCR assays. Asterisks show the statistically significant differences from the corresponding controls, $P < 0.05$; bars represent mean values \pm SE, $n = 8-12$ for cell lines, $n = 5$ for monocytes. CTL, control; MI, median intensity of signal; FC, fold change from CTL; GM-CSF, granulocyte-macrophage colony stimulating factor (20 ng/mL), used to support survival/growth of monocytes in primary culture.

Annexin V and propidium iodide staining

AML cells were induced to apoptosis by 100 μ mol/L AraC (Sigma) for 24 hours. Samples were collected, washed once with PBS, and resuspended in the 10 mmol/L HEPES/NaOH binding buffer, containing 0.14 mol/L NaCl and 2.5 mmol/L CaCl_2 , pH 7.5. Apoptotic cells were stained using an Annexin V-FITC Kit (Sigma). Cells were incubated with 50 μ g/mL Annexin V and 20 μ g/mL PI in the dark, at room temperature for 10 minutes, and immediately analyzed by flow cytometry (EPICS XL). Cells Annexin V positive/PI negative were considered as early apoptotic, cells doubly positive, as late apoptotic.

Western blotting

Western blotting was done using whole-cell extracts as described before (23). Briefly, membranes were incubated overnight with different primary antibodies and then blotted with a HRP-linked secondary antibodies for 1 hour. The protein bands were visualized using a chemiluminescence assay system (Pierce Biotechnology), each membrane was stripped and reprobred for internal control (Crk-L or calregulin). The optical density of each band was quantitated using ImageQuant 5.0 (Molecular Dynamics).

Statistical methods

Each experiment was conducted at least 3 times. The results were expressed relative to vehicle controls, or as percentages of the cell population (mean \pm SE). Significance of the differences between mean values was assessed by a 2-tailed Student's *t* test. All computations were done with an IBM-compatible personal computer using Microsoft EXCEL.

Results

Upregulation of miR-32 by 1,25D in HL60 and U937 cells


The initial experiments were conducted using a miRNA microarray platform (24) to identify the expression of miRNAs after exposure to 1,25D. IPA indicated that only miR-32 was differentially expressed in both HL60 and U937 1,25D-treated cells. As shown in Figure 1A, miR-32 was markedly (~ 11 -fold) and highly significantly increased in HL60 cells, but the increase was less marked and below the level of statistical significance in U937 cells. However, validation of these results by quantitative real-time PCR, shown in Figure 1B, showed that although the increase in miR-32 level was less marked in U937 than in HL60 cells, the increase was statistically significant in both cell lines. Although TaqMan results were less dramatic than those obtained by the microarray, they were clearly confirmatory.

Treatment with 1,25D of monocytes isolated from healthy volunteers also significantly ($P < 0.01$) increased miR-32 levels.

The proapoptotic protein Bim is a potential target of miR-32 in AML cells

In silico studies reported in at least 6 public searches (Fig. 2A) revealed that 3'-UTR of *BCL2L11* gene, which encodes the proapoptotic protein Bim (14, 15), has a potential miR-32 binding site at chromosome 2q13, which is conserved between human and murine genomes (Fig. 2B). Direct regulation in AML cells of Bim protein expression by miR-32 was suggested by the marked decrease in Bim mRNA and Bim protein, its largest isoform known as Bim-EL (15), in both HL60 and U937 cells after exposure to 1,25D (Fig. 2C). This is consistent with the report that in human prostate cancer cells LNCaP, a luciferase reporter construct containing *BCL2L11* 3'-UTR with

Figure 2. Bim has a potential miR-32 binding site and is downregulated by 1,25D in HL60 and U937 cells. **A**, six public web sites examined all predict miR-32 target sites in the 3'-UTR of human *Bim* gene. **B**, schematic representation of the potential miR-32 binding sites within the 3'-UTR of human and mouse *Bim* genes. **C**, Bim mRNA and protein levels are decreased in AML cells exposed to 1,25D for 48 hours. HL60 cells were exposed to 1 nmol/L 1,25D, whereas the less 1,25D-sensitive U937 cells were exposed to 10 nmol/L 1,25D. The levels of Bim mRNA were determined by SYBRGreen qRT-PCR. The asterisks show statistically significant differences from the corresponding controls (CTL). $P < 0.05$; bars represent mean values \pm SE, $n = 4$. The levels of Bim protein were determined by Western blotting and representative blots of 4 experiments are shown here with signal densities indicated below each panel. Calregulin was used as a loading control.



the predicted miR-32 target sequence, showed translational inhibition by miR-32 (25). Although cell type-restricted specificity of miRNA targets is well known, this suggests that Bim may be a general target of miR-32 in human cells.

Expression of Bim is regulated by miRNAs

To confirm that the above predictions apply to AML cells, we first tested whether an interference with miRNA processing affects Bim protein expression in these cells. To accomplish this we reduced the levels of the RNases which process miRNA precursors, the RNase III Drosha, which processes miRNAs in the nucleus, and the cytosolic RNase III, Dicer (26–29). As shown in Figure 3A, transfection of silencing constructs of Dicer and Drosha effectively abrogated 1,25D-induced upregu-

lation of miR-32 expression, though the ambient levels of miR-32 transcripts were not sufficiently reduced to detect statistical significance. As expected, the changes in Bim protein levels were reciprocally affected by the reduction in miRNA-processing enzymes, with decreased Bim levels noted after 1,25D exposure, which were abrogated and actually increased by Dicer and Drosha (Fig. 3B). The increase in Bim levels when miRNA processing is reduced corroborates that Bim expression is regulated by a miRNA or several miRNAs.

Precursor and antisense miR-32 regulate Bim protein levels

To establish that miR-32 is at least one of the miRNAs which affected Bim protein expression when the processing of




Figure 3. The expression of Bim protein is regulated by miRNA. Transfection of siRNA against miRNA-processing enzymes Drosha or Dicer results in (A) abrogation of 1,25D-induced increase in the expression of miR-32 and (B) increased expression of Bim protein in HL60 and U937 cells. siRNA (20 nmol/L) against Drosha or Dicer, or the nontargeting control (denoted siCTL in A, or NT-CTL in B) oligonucleotides were transfected into the cells for 48 hours, and then the cells were exposed to 1 nmol/L (HL60) or 10 nmol/L (U937) 1,25D for a further 24 hours. The level of miR-32 was determined by TaqMan qRT-PCR. #, the statistically significant differences in 1,25D-treated cells (lanes 2 and 8) from the vehicle-treated cells (lanes 1 and 7). *, significant differences from the corresponding siCTL group, apparent only in 1,25D-treated groups. $P < 0.05$; bars represent mean values \pm SE, $n = 4$. The levels of Bim protein and the loading control Crk-L were determined by Western blotting. Band densities are shown below each panel, which are representative blots of 3 experiments. NT, siCTL, nontargeting siRNA control; siDi, siRNA against Dicer; siDr, siRNA against Drosha. *, significant differences from the corresponding siCTL group, apparent only in 1,25D-treated groups. $P < 0.05$; bars represent mean values \pm SE, $n = 4$. The levels of Bim protein and the loading control Crk-L were determined by Western blotting. Band densities are shown below each panel, which are representative blots of 4 experiments. NT, siCTL, nontargeting siRNA control; siDi, siRNA against Dicer; siDr, siRNA against Drosha.

miRNAs was inhibited, we used antisense miR-32 oligonucleotides (anti-miR-32) and precursor miR-32 (pre-miR-32) to modulate cellular levels of miR-32. Under the conditions employed, anti-miR-32 produced a significant decrease in the cellular levels of endogenous miR-32 (Fig. 4A, bars 3–4) with corresponding increases in Bim mRNA (Fig. 4B, bars 3–4) and protein (Fig. 4C). Conversely, pre-miR-32 resulted in

significant increases in cellular levels of miR-32 (Fig. 4A, bars 7–8), whereas Bim mRNA (Fig. 4B, bars 7–8) and protein (Fig. 4D) levels decreased. This indicates that Bim is a target of miR-32 in AML cells, and that 1,25D-induced downregulation of Bim can be reversed by anti-miR-32. In contrast, the levels of Bax, another proapoptotic protein, are essentially unaltered by the manipulation of miR-32 cellular levels (Fig. 4C and D).




Figure 4. Modulation of miR-32 expression by antisense oligonucleotides or by miR-32 precursor results in reciprocal changes in the expression of Bim mRNA and protein in AML cells. **A**, HL60 and U937 cells were transfected with 20 nmol/L antisense oligonucleotides against miR-32 (lanes 3 and 4) or 20 nmol/L pre-miR-32 (lanes 7 and 8) for 48 hours, then exposed to 1 and 10 nmol/L 1,25D, respectively, for a further 48 hours. MiR-32 levels were determined by TaqMan qRT-PCR. #, the statistically significant differences in 1,25D-treated cells (lane 2 or lane 6) from the corresponding vehicle-treated cells (lanes 1 and 5). *, the statistically significant differences from the corresponding (scrambled) controls transfected with nontargeting scrambled oligos (scrambled-A, lane 1 vs. anti-miR-32 lane 3; or scrambled-P lane 5 vs. pre-miR-32, lane 7). A comparison is also shown for 1,25D-treated cells (lane 4 vs. lane 2, and lane 8 vs. lane 6). $P < 0.05$; bars represent mean values \pm SE, $n = 4$. **B**, Bim mRNA levels were determined by SYBRGreen qRT-PCR in the experiments described in (A) above. **C**, levels of Bim and Bax proteins after transfection of anti-miR-32, and (D) pre-miR-32, as determined by Western blotting. Crk-L was used as a loading and transfer control. OD ratio of each band versus CrkL is shown below each panel, which is representative of 3 experiments.

Precursor miR-32 promotes 1,25D-induced AML cell differentiation, whereas antisense miR-32 inhibits differentiation

It has been observed that the processes associated with cell maturation and acquisition of function include cell increased cell survival capacity (30–32). We therefore determined the effect on 1,25D-induced differentiation of the modulation of cellular miR-32 levels by anti-miR-32 or pre-miR-32 and found that anti-miR-32 inhibited cell differentiation (Fig. 5A), whereas pre-miR-32 enhanced differentiation (Fig. 5B). Thus, the changes in the expression of cell surface markers of the monocytic phenotype CD11b and CD14 (Fig. 5) paralleled the cellular levels of miR-32 shown in Figure 4A. The enhancement of monocytic differentiation by pre-miR-32 was also shown by the increased expression of the cytoplasmic esterase NSE, another marker of monocytic phenotype (data

not shown). Thus, perhaps indirectly, miR-32 has a minor but clear role in monocytic differentiation.

Inhibition of miR-32 expression by anti-miR-32 increases the toxicity of AraC to AML cells

The observed effects of miR-32 on the expression of Bim protein suggest that a reduction of cellular levels of miR-32 should make AML cells more susceptible to the therapeutic agents used to treat this disease, generally AraC. This was tested by preincubating AML cells for 48 hours with anti-miR-32, then treating the cells with 100 μ mol/L AraC for 24 hours, and determining Trypan Blue permeability, an indication of necrosis, and the estimation of apoptosis by Annexin V, as well as by the sub G_1/G_0 fraction obtained from flow cytometric measurement of cell-cycle distribution. All 3 sets of determinations showed that anti-miR-32 increases cell death induced




Figure 5. Modulation of miR-32 expression by antisense miR-32 and precursor miR-32 influences 1,25D-induced AML cell differentiation. A, effects of anti-miR-32 on 1,25D-induced differentiation of HL60 and U937 cells. B, effects of pre-miR-32 on 1,25D-induced differentiation. The conditions and symbols are described in the legend to Figure 4 and the determination of differentiation markers in Materials and Methods.

by AraC (Table 1, groups 3 and 4, 7, and 8) and abrogates the previously reported antiapoptotic effect of 1,25D (31). The protective effect of 1,25D is seen here for HL60 cells (Table 1, group 1 vs. group 2), although the complexity of the transfection system does not make this apparent in U937 cells. Anti-miR-32 also enhanced apoptosis when doxorubicin or daunomycin were used as the toxic agents (data not shown).

The complementary approach, the use of pre-miR-32, to show the protective effect of miR-32 on AML cell survival, confirmed the protective effect (Table 1). In the experiments in which pre-miR-32 was transfected the changes in cell survival were less marked than those obtained with anti-miR-32, with AraC-induced necrosis not being significantly affected, and only early apoptosis detectable in U937 cells not treated with 1,25D (Table 1, group 15). This is perhaps seen because other components of cell survival network play a greater role than Bim when pre-miR-32 reduces Bim levels, although increased Bim levels in cells treated with anti-miR-

32 have a more dominant effect on cell survival. Taken together, the 2 approaches clearly show that the response of AML cells to therapeutic cytotoxic agents may be increased by lowering cellular miR-32 levels. This raises the possibility that the combination of differentiation (by 1,25D) with cytotoxic (AraC) therapy may be further enhanced by agents or conditions which lower cellular miR-32 levels, such as anti-miR-32.

Discussion

The studies reported here provide several mechanistic insights and may also have a translational significance. They reveal a novel aspect of the mechanism of vitamin D action, have a bearing on the specificity of miRNA targets, and enhance the understanding of AML cell survival mechanisms. The latter may point the way to increasing the effectiveness of AraC-based induction of disease-free patient survival.

Table 1. Toxicity of AraC to AML cells is modulated by miR-32

Groups	Cells	Treatment	Viability Mean± SD (%)	Early-Apts Mean± SD (%)	Late-Apts Mean± SD (%)	Total-Apts Mean± SD (%)	SubG1 Mean± SD (%)
Anti-miR-32 increases toxicity of AraC to HL60 and U937 cells							
1	HL60	Scrambled-A-C	79.3 ± 6.8	9.6 ± 2.9	22.3 ± 6.4	31.9 ± 6.5	9.9 ± 4.4
2	HL60	Scrambled-A-D	75.3 ± 1.0.5	7.6 ± 1.7	16.7 ± 7.7	24.3 ± 6.6	6.0 ± 2.1
3	HL60	Anti-miR-32-C	65.3 ± 8.3	9.7 ± 1.3	31.9 ± 7.9	41.6 ± 6.5	16.6 ± 4.7
4	HL60	Anti-miR-32-D	63.0 ± 10.3	10.9 ± 2.4	31.3 ± 7.7	42.2 ± 9.5	13.2 ± 3.5
5	U937	Scrambled-A-C	70.3 ± 5.0	10.4 ± 1.2	33.3 ± 6.6	43.7 ± 7.0	8.6 ± 1.5
6	U937	Scrambled-A-D	71.7 ± 4.2	9.5 ± 1.7	32.1 ± 3.6	41.6 ± 4.1	7.6 ± 3.1
7	U937	Anti-miR-32-C	61.0 ± 5.5	10.5 ± 2.1	45.1 ± 6.9	55.6 ± 3.1	11.4 ± 2.1
8	U937	Anti-miR-32-D	63.3 ± 3.8	9.1 ± 2.4	40.7 ± 7.0	49.8 ± 4.2	12.5 ± 2.7
Pre-miR-32 reduces toxicity of AraC to HL60 and U937 cells							
9	HL60	Scrambled-P-C	77.0 ± 11.5	9.0 ± 2.2	27.3 ± 4.8	36.3 ± 6.7	8.4 ± 1.6
10	HL60	Scrambled-P-D	79.0 ± 10.5	7.0 ± 1.6	19.9 ± 4.9	26.9 ± 7.8	6.4 ± 1.8
11	HL60	Pre-miR-32-C	79.5 ± 11.5	7.0 ± 1.2	14.9 ± 3.7	21.9 ± 5.5	4.7 ± 1.6
12	HL60	Pre-miR-32-D	80.5 ± 10.5	7.1 ± 2.1	13.8 ± 4.2	20.9 ± 6.1	4.0 ± 1.5
13	U937	Scrambled-P-C	61.0 ± 5.1	15.3 ± 1.2	36.9 ± 6.3	52.2 ± 7.2	8.6 ± 1.9
14	U937	Scrambled-P-D	62.3 ± 7.2	12.5 ± 1.8	43.2 ± 6.0	55.7 ± 7.5	7.8 ± 2.3
15	U937	Pre-miR-32-C	67.5 ± 6.0	6.6 ± 1.0	35.5 ± 5.9	42.1 ± 7.1	5.3 ± 1.5
16	U937	Pre-miR-32-D	68.0 ± 6.1	12.4 ± 1.9	27.6 ± 5.7	40.0 ± 7.3	4.9 ± 1.4

NOTE: Inhibition of miR-32 expression by antisense oligonucleotides increases the toxicity of AraC to HL60 and U937 cells. HL60 and U937 cells were transfected with 20 nmol/L antisense oligonucleotides against miR-32 for 48 hours and then exposed to 1 nmol/L (HL60) or 10 nmol/L (U937) 1,25D for further 48 hours. Then the cells were exposed to 100 μmol/L AraC for further 24 hours. To detect apoptosis, cells were stained using 50 μg/mL Annexin V and 20 μg/mL PI and analyzed by flow cytometry. Annexin V-positive/PI-negative cells were considered as early apoptotic, cells doubly positive, as late apoptotic. **Bold type** shows the statistically significant differences from the corresponding scrambled controls. $P < 0.05$; mean values ± SD are shown, $n = 4$. C, vehicle control; D, 1,25D-treated; A, anti-miR-32; P, pre-miR-32; Apts, apoptosis.

Previous work in our and other laboratories has shown that 1,25D-induced differentiation of human AML cells is accompanied by increased cell survival capacity, which is likely to be multifactorial. These include activation of the ERK, an AKT pathways (33–36), although the specific details about the sequence of molecular events are few. One possibility is that the *hKSR2* gene, which is directly upregulated by 1,25D (37), provides an upstream platform for activation of mitogen-activated protein kinase pathways, which then signal prosurvival events, as has been shown by knockdown of *hKSR2* expression (31). The prosurvival events include upregulation of the antiapoptotic Mcl-1 (30) and altered Bcl-2/Bad ratios (31). Here, we document a role for miR-32 in the prosurvival events, but its relationship to the other signaling members of apoptosis/survival network remains to be elucidated.

The exquisite cell context specificity of miRNA targets is well known, and any given mRNA may be targeted by different miRNAs in different cell types or even cell subtypes. (e.g., refs. 38, 39). It is therefore important to note that in both HL60 and U937 cells, which belong to different FAB subtypes, miR-32 targets Bim (Fig. 4). Also, recent studies in the Croce laboratory have shown that in 2 subtypes of cultured human prostate cancer cells, miR-32 inhibits the expression of Bim by a

3'-UTR-mediated mechanism (25). Taken together with results reported here, this suggests that the miR-32–Bim relationship is of wide significance in human cells. This contrasts with the targeting of p27Kip1 by miR-181 previously reported in AML cells (23, 40), whereas in a variety of solid tumors p27Kip1 is targeted by miR-221/222 (41–43). These examples show that miRNA targets need to be established 1 cell type at a time.

Currently, there are only a few published reports of the ability of 1,25D to regulate key cellular functions through modulation of miRNA expression. Previously, we showed that an exposure of human AML HL60 and U937 cells to 1,25D results in downregulation of the miR-181 family, with the most prominent effect on miR-181a (23). This was associated with the upregulation of p27Kip1 expression and contributed to 1,25D-induced cell-cycle arrest. More recently, miR-24 was reported to be upregulated by 1,25D and related to diminished cell proliferation (44), and a role for miRNA in cell-cycle control by 1,25D was described in cultured nonmalignant RWPE-1 human prostate epithelial cells (45). In RWPE-1 cells 1,25D upregulates the DNA helicase *MCM7* gene, in which the miR-106 is embedded in intron 13 (46, 47), which then targets p21/CDKN1A and contributes to cell-cycle arrest. Thus, this article provides a new aspect of the accumulating evidence that miRNAs participate in the critical aspects of vitamin D

regulation of the essential cellular processes, such as those controlling the cell cycle, cell survival, and cell differentiation.

Selective upregulation of miR-32 in at least some human cancers, including prostate carcinoma and multiple myeloma, (25, 48) seems to play a role in malignant transformation by providing survival advantage to cells with high expression of miR-32 and reduced levels of Bim. A similar mechanism described here seems to aid the phagocytic function of monocytes, which produces intracellular stress as a consequence of generation of ROS needed to dispose of phagocytized material. But because increased survival capacity is a disadvantage when malignant cells are to be eradicated by cytotoxic agents, consideration should be given to the design of differentiation therapy regimens in which compounds or conditions which reduce the expression of miR-32, or increase

the levels of Bim (49, 50), are administered along with the therapeutic agents.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

The study was supported by the NIH Grant RO1-CA-044722-21 (to G.P. Studzinski) and by the Polish Science Foundation (to E. Gocek).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 18, 2011; revised July 7, 2011; accepted July 27, 2011; published OnlineFirst August 4, 2011.

References

- Shiple J, Butera JN. Acute myelogenous leukemia. *Exp Hematol* 2009;37:649–58.
- Miyaura C, Abe E, Kuribayashi T, Tanaka H, Konno K, Nishii Y, et al. 1- α ,25-dihydroxyvitamin D₃ induces differentiation of human myeloid leukemia cells. *Biochem Biophys Res Commun* 1981;102:937–43.
- Koeffler HP. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. *Blood* 1983;62:709–21.
- Studzinski GP, Bhandal AK, Brelvi ZS. A system for monocytic differentiation of leukemic cells HL 60 by a short exposure to 1,25-dihydroxycholecalciferol. *Proc Soc Exp Biol Med* 1985;179:288–95.
- Wang X, Studzinski GP. Inhibition of p38MAP kinase potentiates the JNK/SAPK pathway and AP-1 activity in monocytic but not in macrophage or granulocytic differentiation of HL60 cells. *J Cell Biochem* 2001;82:68–77.
- Wang Q, Wang X, Studzinski GP. Jun N-terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1,25-dihydroxyvitamin D₃. *J Cell Biochem* 2003;89:1087–101.
- Pan Z, Hetherington CJ, Zhang DE. CCAAT/enhancer-binding protein activates the CD14 promoter and mediates transforming growth factor beta signaling in monocyte development. *J Biol Chem* 1999;274:23242–8.
- Studzinski GP, Wang X, Ji Y, Wang Q, Zhang Y, Kutner A, et al. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. *J Steroid Biochem Mol Biol* 2005;97:47–55.
- Marcinkowska E, Garay E, Gocek E, Chrobak A, Wang X, Studzinski GP. Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D₃. *Exp Cell Res* 2006;312:2054–65.
- Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): I. As₂O₃ exerts dose-dependent dual effects on APL cells. *Blood* 1997;89:3345–53.
- Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. *Leukemia* 2001;15:735–41.
- Studzinski GP, Bhandal AK, Brelvi ZS. Potentiation by 1- α ,25-dihydroxyvitamin D₃ of cytotoxicity to HL-60 cells produced by cytarabine and hydroxyurea. *J Natl Cancer Inst* 1986;76:641–8.
- Studzinski GP, Reddy KB, Hill HZ, Bhandal AK. Potentiation of 1- β -D-arabinofuranosylcytosine cytotoxicity to HL-60 cells by 1,25-dihydroxyvitamin D₃ correlates with reduced rate of maturation of DNA replication intermediates. *Cancer Res* 1991;51:3451–5.
- O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. *EMBO J* 1998;17:384–95.
- Bouillet P, Zhang LC, Huang DC, Webb GC, Bottema CD, Shore P, et al. Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. *Mamm Genome* 2001;12:163–8.
- Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. *Blood* 1979;54:713–33.
- Gocek E, Kielbinski M, Bauraska H, Haus O, Kutner A, Marcinkowska E. Different susceptibilities to 1,25-dihydroxyvitamin D₃-induced differentiation of AML cells carrying various mutations. *Leuk Res* 2010;34:649–57.
- Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res* 2006;34:D140–4.
- Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. *RNA* 2004;10:1507–17.
- Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. *Nucleic Acids Res* 2008;36:D149–53.
- Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 2005;120:15–20.
- Chen K, Rajewsky N. Natural selection on human microRNA binding sites inferred from SNP data. *Nat Genet* 2006;38:1452–6.
- Wang X, Gocek E, Liu CG, Studzinski GP. MicroRNAs181 regulate the expression of p27^{Kip1} in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D₃. *Cell Cycle* 2009;8:736–41.
- Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. *Oncogene* 2007;26:4148–57.
- Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. *Cancer Res* 2008;68:6162–70.
- Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. *EMBO J* 2002;21:4663–70.
- Provost P, Dishart D, Doucet J, Frensdewey D, Samuelsson B, Radmark O. Ribonuclease activity and RNA binding of recombinant human Dicer. *EMBO J* 2002;21:5864–74.
- Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. *Nature* 2003;425:415–9.
- Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. *Science* 2004;303:95–8.
- Wang X, Studzinski GP. Antiapoptotic action of 1,25-dihydroxyvitamin D₃ is associated with increased mitochondrial MCL-1 and RAF-1

- proteins and reduced release of cytochrome c. *Exp Cell Res* 1997;235:210–7.
31. Wang X, Patel R, Studzinski GP. hKSR-2, a vitamin D-regulated gene, inhibits apoptosis in arabinocytosine-treated HL60 leukemia cells. *Mol Cancer Ther* 2008;7:2798–806.
 32. Lombardero M, Kovacs K, Scheithauer BW. Erythropoietin: a hormone with multiple functions. *Pathobiology* 2011;78:41–53.
 33. Wang X, Studzinski GP. Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D₃-induced differentiation of HL60 cells. *J Cell Biochem* 2001;80:471–82.
 34. Marcinkowska E, Kutner A. Side-chain modified vitamin D analogs require activation of both PI 3-K and Erk1,2 signal transduction pathways to induce differentiation of human promyelocytic leukemia cells. *Acta Biochim Pol* 2002;49:393–406.
 35. Zhang Y, Zhang J, Studzinski GP. AKT pathway is activated by 1, 25-dihydroxyvitamin D₃ and participates in its anti-apoptotic effect and cell cycle control in differentiating HL60 cells. *Cell Cycle* 2006;5:447–51.
 36. Gocek E, Kielbinski M, Marcinkowska E. Activation of intracellular signaling pathways is necessary for an increase in VDR expression and its nuclear translocation. *FEBS Lett* 2007;581:1751–7.
 37. Wang X, Wang TT, White JH, Studzinski GP. Expression of human kinase suppressor of Ras 2 (hKSR-2) gene in HL60 leukemia cells is directly upregulated by 1,25-dihydroxyvitamin D₃ and is required for optimal cell differentiation. *Exp Cell Res* 2007;313:3034–45.
 38. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. *Blood* 2009;113:396–402.
 39. Debernardi S, Skoulakis S, Molloy G, Chaplin T, Dixon-Mclver A, Young BD. MicroRNA miR-181a correlates with morphological subclass of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. *Leukemia* 2007;21:912–6.
 40. Cuesta R, Martinez-Sanchez A, Gebauer F. miR-181a regulates cap-dependent translation of p27^{Kip1} mRNA in myeloid cells. *Mol Cell Biol* 2009;29:2841–51.
 41. Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM, et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. *Cancer Res* 2008;68:2773–80.
 42. Gillies JK, Lorimer IA. Regulation of p27^{Kip1} by miRNA 221/222 in glioblastoma. *Cell Cycle* 2007;6:2005–9.
 43. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27^{Kip1} protein levels and cell cycle. *Endocr Relat Cancer* 2007;14:791–8.
 44. Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E, et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. *Mol Cell* 2009;35:610–25.
 45. Thorne JL, Maguire O, Doig CL, Battaglia S, Fehr L, Sucheston LE, et al. Epigenetic control of a VDR-governed feed-forward loop that regulates p21^{Waf1/Cip1} expression and function in non-malignant prostate cells. *Nucleic Acids Res* 2011;39:2045–56.
 46. Saramaki A, Banwell CM, Campbell MJ, Carlberg C. Regulation of the human p21^{Waf1/Cip1} gene promoter via multiple binding sites for p53 and the vitamin D₃ receptor. *Nucleic Acids Res* 2006;34:543–54.
 47. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. *Mol Cell Biol* 2008;28:2167–74.
 48. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. *Proc Natl Acad Sci U S A* 2008;105:12885–90.
 49. Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. *Cancer Cell* 2005;7:227–38.
 50. Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, et al. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. *Blood* 2009;114:4507–16.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

MicroRNA-32 Upregulation by 1,25-Dihydroxyvitamin D₃ in Human Myeloid Leukemia Cells Leads to Bim Targeting and Inhibition of AraC-Induced Apoptosis

Elzbieta Gocek, Xuening Wang, Xiuping Liu, et al.

Cancer Res 2011;71:6230-6239. Published OnlineFirst August 4, 2011.

Updated version Access the most recent version of this article at:
doi:[10.1158/0008-5472.CAN-11-1717](https://doi.org/10.1158/0008-5472.CAN-11-1717)

Cited articles This article cites 50 articles, 19 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/71/19/6230.full#ref-list-1>

Citing articles This article has been cited by 7 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/71/19/6230.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/71/19/6230>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.